Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus

Acta Diabetologica

Volumn 44, Issue 3, 2007, Pages 149-156

  Turkmen Kemal Y ^a   Guvener Demirag N ^a   Yildirir, A ^a   Atar, A ^a   Dogruk Unal, A ^a   Biyiklioglu, Z ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Brain natriuretic peptide; Myocardial performance index; Rosiglitazone

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HEART FUNCTION; HEART PERFORMANCE; HEART VENTRICLE CONTRACTILITY; HUMAN; LABORATORY TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART FUNCTION TESTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; THIAZOLIDINEDIONES; VENTRICULAR FUNCTION, LEFT;

EID: 34548157696     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-007-0256-4     Document Type: Article

References (33)

1. Reaven G (2002) Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106:286-288
2. Coats AJ, Anker SD (2000) Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 35: S9-S14. Erratum in: J Cardiovasc Pharmacol 2001; 38:490 Anker S [corrected to Anker SD]
3. Mudaliar S, Henry RR (2001) New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-257
4. Niemeyer NV, Janney LM (2002) Thiazolidinedione-induced edema. Pharmacotherapy 22:924-929
5. Thomas ML, Lloyd SJ (2001) Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 35:123-124
6. Wooltorton E (2002) Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ 166:219
7. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group (2001) A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24:1226-1232
8. Hartung DM, Touchette DR, Bultemeier NC, Haxby DG (2005) Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy 25:1329-1336
9. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680-1689
10. Idris I, Gray S, Donnelly R (2003) Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 46:288-290
11. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrisey R, Garcia A, Chiu A, De Maria A (2001) Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141:367-374
12. Moe GW (2005) BNP in the diagnosis and risk stratification of heart failure. Heart Fail Monit 4:116-122
13. Arnlov J, Ingelsson E, Riserus U, Andren B, Lind L (2004) Myocardial performance index, a Doppler-derived index of global left ventricular function, predicts congestive heart failure in elderly men. Eur Heart J 25:2220-2225
14. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, Seward JB (1995) New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function - a study in normals and dilated cardiomyopathy. J Cardiol 26:357-366
15. Tei C, Nishimura RA, Seward JB, Tajik AJ (1997) Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 10:169-178
16. Tekten T, Onbasili AO, Ceyhan C, Unal S, Discigil B (2003) Value of measuring myocardial performance index by tissue Doppler echocardiography in normal and diseased heart. Jpn Heart J 44:403-416
17. Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, Maisel A (2002) A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 144:834-839
18. Thomas ML, Lloyd SJ (2001) Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 35:123-124
19. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866
20. Guan Y, Zhang Y, Davis L, Breyer MD (1997) Expression of perosisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 273:F1013-F1022
21. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC 3rd, Schnermann JB, Briggs JP (1999) Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 277:F966-F973
22. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA (2004) Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 308:426-433
23. Ogawa S, Takeuchi K, Ito S (2003) Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab 88:3993-3996
24. Shim WS, Do MY, Kim SK, Kim HJ, Hur KY, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS (2006) The long term effects of rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol 65:453-459
25. Sartori M, Ceolotto G, Semplicini A (1999) MAPKinase and regulation of the sodium-proton exchanger in human red blood cell. Biochim Biophys Acta 1421:140-148
26. Hirsch IB, Kelly J, Cooper S (1999) Pulmonary edema associated with troglitazone therapy. Arch Intern Med 159:1811
27. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A (2000) Peroxisome prolifer-atoractivated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102:1834-1839
28. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, Sato K, Taniyama Y, Ito S (2001) Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142:3125-3134
29. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL (2002) Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105:2296-2302
30. Graf K, Xi XP, Hsueh WA, Law RE (1997) Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett 400:119-121
31. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I (2002) Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240-1246
32. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K (2001) Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104:1670-1675
33. Wang F, Vergara C, Carabino J, Desilets A, Vasquez R (2004) Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms. Am J Health Syst Pharm 61:1604-1608